INST Committee Meeting
Notices of Meeting include information about the subject matter to be examined by the committee and date, time and place of the meeting, as well as a list of any witnesses scheduled to appear. The Evidence is the edited and revised transcript of what is said before a committee. The Minutes of Proceedings are the official record of the business conducted by the committee at a sitting.
For an advanced search, use Publication Search tool.
If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.
MINUTES OF PROCEEDINGS
Meeting No. 28
Tuesday, May 29, 2001
The Standing Committee on Industry, Science and Technology met at 3:35 p.m. this day, in Room 308, West Block, the Chair, Susan Whelan, presiding.
Members of the Committee present: Pierre Brien, Scott Brison, John Cannis, Bev Desjarlais, Marlene Jennings, Walt Lastewka, Dan McTeague, Charlie Penson, James Rajotte, Paddy Torsney and Susan Whelan.
Acting Members present: John McCallum for Reg Alcock, Réal Ménard for Jocelyne Girard-Bujold, Jacques Saada for Reg Alcock and Wayne Easter for Andy Savoy.
In attendance: From the Library of Parliament: Geoffrey P. Kieley, Research Officer.
Witnesses: From the Canadian Chamber of Commerce: Michael N. Murphy, Senior Vice-President, Policy. From the Coalition for Biomedical and Health Research: Lisa McKerracher, Associate Professor, Department of Pathology and Cell Biology, Université de Montréal; Charles Pitts, Executive Director. From BIOTECanada: Janet Lambert, President. From Canada's Research-Based Pharmaceutical Companies: James E. Mills, Barristers and Solicitors, Patent and Trade Mark Agents; Terry McCool, Vice-President, Corporate Affairs, Eli Lilly Canada Inc., Vice-President, Intellectual Property Committee. From the Department of Industry: Andreï Sulzenko, Assistant Deputy Minister, Industry and Science Policy; Robert Main, Acting Director General, Corporate Governance Branch; Susan Bincoletto, Director, Special Projects Directorate; Rob Sutherland-Brown, Senior Legal Counsel.
Pursuant to its Order of Reference of Tuesday, May 15, 2001, the Committee resumed consideration of Bill S-17, An Act to amend the Patent Act (See Minutes of Proceedings, Tuesday, May 15, 2001, Meeting No. 24).
Michael Murphy, Charles Pitts, Janet Lambert, Terry McCool each made an opening statement and, with the other witnesses answered questions.
By unanimous consent, the Committee distributed a response from the Canadian Drug Manufacturers Association to the Chair of the Committee dated May 28, 2001.
At 5:40 p.m., the sitting was suspended.
At 6:10 p.m., the sitting resumed.
The Committee proceeded to Clause-by-Clause consideration of the Bill.
The Title carried on division.
Clause 1 carried on division.
Clause 2 carried on division.
Clause 3 carried on division.
Clause 4 carried on division.
Clause 5 carried on division.
The Bill, carried.
ORDERED, -- That the Chair report Bill S-17 without amendments to the House as the First Report of the Committee.
By unanimous consent, the Committee proceeded to consider the Main Estimates 2001-2002.
It was agreed, -- That the Committee adopt the Main Estimates for the fiscal year 2001-2002, without amendments, and report the same to the House as the Second Report of the Committee.
At 6:30 p.m., the Committee adjourned to the call of the Chair.
Normand Radford
Clerk of the Committee